If you're researching hormone therapy, you've probably encountered very different messaging. Some sources present it as natural and risk‑free; others suggest it is dangerous. Neither extreme is accurate. This page is an educational summary of the evidence.

The Backdrop: The Women's Health Initiative (WHI)

The WHI was a large randomized controlled trial published in 2002. The estrogen‑plus‑progestin arm showed increases in certain risks — breast cancer, stroke, venous thromboembolism — in postmenopausal women on the combined regimen used in the trial. Subsequent reanalysis has produced a more nuanced picture: the "timing hypothesis" (starting near menopause has different risk‑benefit than starting later), differences between oral and transdermal routes, and differences between estrogen‑only and combined therapy. Current understanding is that for appropriately selected patients starting near menopause, hormone therapy has a favorable risk‑benefit profile.

What Is Generally Considered Established

• Hormone therapy is effective for vasomotor symptoms (hot flashes, night sweats) — the most effective treatment available.
• Vaginal hormone therapy for genitourinary symptoms achieves high local effects with low systemic absorption.
• Hormone therapy has some risks: small increased risk of VTE (lower with transdermal), increased risk of stroke based on age and formulation, small increased risk of breast cancer with longer‑duration combined therapy, and increased endometrial cancer risk with unopposed estrogen in women with a uterus (which is why progesterone is added).
• Risk‑benefit varies by individual. The same therapy may be appropriate for one woman and inappropriate for another.

What's Less Settled About Compounded Preparations

Large head‑to‑head randomized trials directly comparing compounded preparations and approved bioidentical products are limited. Major medical organizations generally consider approved products as first‑line when they match the clinical need. Compounded preparations are considered when customization is needed that approved products don't allow — not as a default substitute. Claims that compounded preparations are categorically "safer" than approved products are not well‑supported by evidence.

What Major Medical Organizations Say

The Menopause Society, The Endocrine Society, and the Society of Obstetricians and Gynaecologists of Canada all state that Health Canada–approved bioidentical products are typically preferred over compounded preparations when an approved product matches the clinical need. Compounded preparations may be appropriate for specific clinical situations — allergies to commercial ingredients, non‑commercial doses, or specific combinations.

Monitoring and Safety in Practice

Patients on hormone therapy should have ongoing monitoring with their prescriber: symptom response, cardiovascular and breast health screening, and discussion of whether to continue, adjust, or stop. Report unexpected vaginal bleeding, breast lumps, severe headaches, leg swelling, chest pain, visual changes, or significant mood changes to your prescriber promptly.

Our Role as a Pharmacy

Our role in compounded hormone therapy is preparing the prescription your prescriber writes — to documented quality standards, with batch records, and counselling you on use of the formulation. We do not recommend hormone therapy for or against your specific situation; clinical decisions remain with your prescriber.